Dr. Vijay Raturi
5/5

(Avg 5 based on 1 rating)

1 / 1 vote

Dr. Vijay Raturi Verified by iCliniq

M.D. (RADIATION ONCOLOGY)., D.N.B. (RADIATION ONCOLOGY)
Professional Bio: 

Dr.Vijay Parshuram Raturi is a Radiation Oncologist with 10 years of clinical experience. He completed his MD in the King George's Medical University, Lucknow, India (Graduated in 2016) and DNB (Ra... Read More 

Experience

10+ Yrs

Languages

English

Patients

Helped 1000 patients

Fee

Query : $19.99

Phone/Video : $29.99

Recent Answers

Professional Bio

Dr.Vijay Parshuram Raturi is a Radiation Oncologist with 10 years of clinical experience. He completed his MD in the King George's Medical University, Lucknow, India (Graduated in 2016) and DNB (Radiation Oncology) at the Directorate of National Board, Delhi. Presently, he is working at the National Cancer Center Hospital East, Japan, for the last 2 years. He treats all cancer subsites using photon and proton therapy. His main focus/research area is using Proton therapy for head and neck and gastrointestinal malignancy.

Academics & Trainings

M.D. (RADIATION ONCOLOGY)

King George's Medical University, Lucknow

2016


D.N.B. (RADIATION ONCOLOGY)

Directorate Of National Board, Delhi

2018

Awards & Publications

He is a visiting Scientist (Particle Therapy and Translational Research) in National Cancer Center Hospital East, Chiba, Japan (17/06/2018 till 30/05/2019) and a research associate (Particle therapy) in the National Cancer Center Hospital East, Chiba, Japan (01/06/2019 till date).

Publications:

a) Multiple Inherited Schwannomas, Meningiomas, and Ependymomas Syndrome in an Adult Patient.

b) A Prospective Randomized Comparison of Concurrent Chemoradiation with Neoadjuvant and Adjuvant Chemotherapy with Concurrent Chemoradiation Alone for Locally Advanced Carcinoma Cervix.

c) Affiliation of XRCC-1 Gene Arg194Trp polymorphism in alcohol and tobacco substance users and loco-regionally progressed LSCC.

d) A Prospective Study Comparing Oxaliplatin & 5-Fu with Gemcitabine & Cisplatin in Advanced Stage Carcinoma Gall Bladder.

e) A Prospective Randomized Comparison of Concurrent Chemoradiation with Neoadjuvant and Adjuvant Chemotherapy with Concurrent Chemoradiation Alone for Locally Advanced Carcinoma Cervix.

f) Hypofractionated proton beam therapy for centrally located lung cancer.

g) Impact of Proton Beam Irradiation of an Anatomic Subsegment of the Liver for Hepatocellular Carcinoma. h) Could excision repair cross-complementing group-1mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?

i) Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation.

j) Efficacy and safety of accelerated fractionated radiotherapy without elective nodal irradiation for T3N0 glottic cancer without vocal cord fixation.

k) Prospective evaluation of the setup errors and their impact on safety margin for cervical cancer pelvic conformal radiotherapy.

l) Treatment patterns and outcomes change in early-stage non-small cell lung cancer in octogenarians and older: a SEER database analysis.

Testimonials

View All

In-Person Consultation

Vijay Raturi

Division Of Radiation Oncology And Particle Therapy, National Cancer Center Hospital East, 6 Chome-5-1 Kashiwanoha,, Kashiwa, Chiba, Zip: 2278577, JP